Chakraborty, R. (2021). Anticancer Drug Approvals in the Past Decade—Quality vs Quantity. JAMA Network Open, 4(12), e2139178. https://doi.org/10.1001/jamanetworkopen.2021.39178

Liu, Y., Wu, Z., Zhou, J., Ramadurai, D. K. A., Mortenson, K. L., Aguilera-Jimenez, E., Yan, Y., Yang, X., Taylor, A. M., Varley, K. E., Gertz, J., Choi, P. S., Cherniack, A. D., Chen, X., Bass, A. J., Bailey, S. D., & Zhang, X. (2021). A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-27055-4

Chen, V., Bo, C., & Gu, W. (2021). The roads to ferroptosis under homeostatic versus pathological conditions. Molecular & Cellular Oncology, 8(5). https://doi.org/10.1080/23723556.2021.1970477

Cable, J., Pei, D., Reid, L. M., Wang, X. W., Bhatia, S., Karras, P., Melenhorst, J. J., Grompe, M., Lathia, J. D., Song, E., Kuo, C. J., Zhang, N., White, R. M., Ma, S. K., Ma, L., Chin, Y. R., Shen, M. M., Ng, I. O. L., Kaestner, K. H., … Weissman, I. L. (2021). Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report. Annals of the New York Academy of Sciences, 1506(1), 142–163. Portico. https://doi.org/10.1111/nyas.14719

Rodriguez, D. A., Yang, J., Durante, M. A., Shoushtari, A. N., Moschos, S. J., Wrzeszczynski, K. O., Harbour, J. W., & Carvajal, R. D. (2021). Multiregional genetic evolution of metastatic uveal melanoma. Npj Genomic Medicine, 6(1). https://doi.org/10.1038/s41525-021-00233-5

Pei, S., Swayne, T. C., Morris, J. F., & Emtage, L. (2021). Threshold concentration and random collision determine the growth of the huntingtin inclusion from a stable core. Communications Biology, 4(1). https://doi.org/10.1038/s42003-021-02460-z

Houghton, L. C., Gibbons, M. P., Shekelle, J., Oakley-Girvan, I., Watterson, J. L., Magsamen-Conrad, K., Jones, C., & Gokal, K. (2021). Free Time For Wellness: a co-designed intervention utilizing social networks to encourage physical activity for cancer prevention among low resourced mothers. BMC Public Health, 21(1). https://doi.org/10.1186/s12889-021-11775-9

Karakasheva, T. A., Gabre, J. T., Sachdeva, U. M., Cruz-Acuña, R., Lin, E. W., DeMarshall, M., Falk, G. W., Ginsberg, G. G., Yang, Z., Kim, M. M., Diffenderfer, E. S., Pitarresi, J. R., Li, J., Muir, A. B., Hamilton, K. E., Nakagawa, H., Bass, A. J., & Rustgi, A. K. (2021). Patient-derived organoids as a platform for modeling a patient’s response to chemoradiotherapy in esophageal cancer. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-00706-8

Welch, C. L., & Chung, W. K. (2021). Genomics of Pulmonary Hypertension. Advances in Pulmonary Hypertension, 20(5), 142–149. https://doi.org/10.21693/1933-088x-20.5.142

Altoe, M. L., Kalinsky, K., Marone, A., Kim, H. K., Guo, H., Hibshoosh, H., Tejada, M., Crew, K. D., Accordino, M. K., Trivedi, M. S., Hershman, D. L., & Hielscher, A. H. (2021). Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast Cancer Research, 23(1). https://doi.org/10.1186/s13058-021-01396-w

Wu, X., Cheng, Y.-S. L., Matthen, M., Yoon, A., Schwartz, G. K., Bala, S., Taylor, A. M., & Momen-Heravi, F. (2021). Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion. Journal of Experimental & Clinical Cancer Research, 40(1). https://doi.org/10.1186/s13046-021-01865-2

Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B. R., & Gu, W. (2021). iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-23902-6

Singh, V., Pencina, M., Einstein, A. J., Liang, J. X., Berman, D. S., & Slomka, P. (2021). Impact of train/test sample regimen on performance estimate stability of machine learning in cardiovascular imaging. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-93651-5

Kremer, D. M., Nelson, B. S., Lin, L., Yarosz, E. L., Halbrook, C. J., Kerk, S. A., Sajjakulnukit, P., Myers, A., Thurston, G., Hou, S. W., Carpenter, E. S., Andren, A. C., Nwosu, Z. C., Cusmano, N., Wisner, S., Mbah, N. E., Shan, M., Das, N. K., Magnuson, B., … Lyssiotis, C. A. (2021). GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-24859-2

Tate, T., Xiang, T., Wobker, S. E., Zhou, M., Chen, X., Kim, H., Batourina, E., Lin, C.-S., Kim, W. Y., Lu, C., Mckiernan, J. M., & Mendelsohn, C. L. (2021). Pparg signaling controls bladder cancer subtype and immune exclusion. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-26421-6

Sheikh, T. N., Chen, X., Xu, X., McGuire, J. T., Ingham, M., Lu, C., & Schwartz, G. K. (2021). Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors. Molecular Cancer Therapeutics, 20(12), 2362–2371. https://doi.org/10.1158/1535-7163.mct-21-0066

Austin, J. D., Tehranifar, P., Rodriguez, C. B., Brotzman, L., Agovino, M., Ziazadeh, D., Moise, N., & Shelton, R. C. (2021). A mixed-methods study of multi-level factors influencing mammography overuse among an older ethnically diverse screening population: implications for de-implementation. Implementation Science Communications, 2(1). https://doi.org/10.1186/s43058-021-00217-7

Laszkowska, M., Kim, J., Faye, A. S., Joelson, A. M., Ingram, M., Truong, H., Silver, E. R., May, B., Greendyke, W. G., Zucker, J., Lebwohl, B., Hur, C., & Freedberg, D. E. (2021). Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19. Digestive Diseases and Sciences, 66(12), 4398–4405. https://doi.org/10.1007/s10620-020-06760-y

Mi, X., Zou, B., Zou, F., & Hu, J. (2021). Permutation-based identification of important biomarkers for complex diseases via machine learning models. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-22756-2

Zhu, N., Swietlik, E. M., Welch, C. L., Pauciulo, M. W., Hagen, J. J., Zhou, X., Guo, Y., Karten, J., Pandya, D., Tilly, T., Lutz, K. A., Martin, J. M., Treacy, C. M., Rosenzweig, E. B., Krishnan, U., Coleman, A. W., Gonzaga-Jauregui, C., Lawrie, A., Trembath, R. C., … Chung, W. K. (2021). Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 13(1). https://doi.org/10.1186/s13073-021-00891-1

Clement, C. C., D’Alessandro, A., Thangaswamy, S., Chalmers, S., Furtado, R., Spada, S., Mondanelli, G., Ianni, F., Gehrke, S., Gargaro, M., Manni, G., Cara, L. C. L., Runge, P., Tsai, W. L., Karaman, S., Arasa, J., Fernandez-Rodriguez, R., Beck, A., Macchiarulo, A., … Santambrogio, L. (2021). 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-24785-3

Wu, H.-C., Yang, H.-I., Lin, P.-H., Chen, C.-J., Santella, R. M., & Terry, M. B. (2021). Reproductive and environmental exposures and the breast cancer risk in Taiwanese women. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-95290-2

Melamed, A., Rauh-Hain, J. A., Gockley, A. A., Nitecki, R., Ramirez, P. T., Hershman, D. L., Keating, N., & Wright, J. D. (2021). Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncology, 7(12), 1782. https://doi.org/10.1001/jamaoncol.2021.4252

Lan, Z., Chen, L., Feng, J., Xie, Z., Liu, Z., Wang, F., Liu, P., Yue, X., Du, L., Zhao, Y., Yang, P., Luo, J., Zhu, Z., Hu, X., Cao, L., Lu, P., Sah, R., Lavine, K., Kim, B., & Hu, H. (2021). Mechanosensitive TRPV4 is required for crystal-induced inflammation. Annals of the Rheumatic Diseases, 80(12), 1604–1614. https://doi.org/10.1136/annrheumdis-2021-220295

Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., & Ho, D. D. (2021). Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-22362-2

Goodwin, P. J., Dowling, R. J. O., Ennis, M., Chen, B. E., Parulekar, W. R., Shepherd, L. E., Burnell, M. J., Vander Meer, R., Molckovsky, A., Gurjal, A., Gelmon, K. A., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Whelan, T. J., Hobday, T. J., Rastogi, P., Rabaglio-Poretti, M., Lemieux, J., … Stambolic, V. (2021). Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 7(1). https://doi.org/10.1038/s41523-021-00275-z

Flashner, S., Yan, K. S., & Nakagawa, H. (2021). 3D Organoids: An Untapped Platform for Studying Host–Microbiome Interactions in Esophageal Cancers. Microorganisms, 9(11), 2182. https://doi.org/10.3390/microorganisms9112182

Cham, S., Li, A., Rauh-Hain, J. A., Tergas, A. I., Hershman, D. L., Wright, J. D., & Melamed, A. (2022). Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncology, 8(1), 159. https://doi.org/10.1001/jamaoncol.2021.5779

Chu, J. N., Collins, J. E., Chen, T. T., Chai, P. R., Dadabhoy, F., Byrne, J. D., Wentworth, A., DeAndrea-Lazarus, I. A., Moreland, C. J., Wilson, J. A. B., Booth, A., Ghenand, O., Hur, C., & Traverso, G. (2021). Patient and Health Care Worker Perceptions of Communication and Ability to Identify Emotion When Wearing Standard and Transparent Masks. JAMA Network Open, 4(11), e2135386. https://doi.org/10.1001/jamanetworkopen.2021.35386

Nitecki, R., Fu, S., Jorgensen, K. A., Gray, L., Lefkowits, C., Smith, B. D., Meyer, L. A., Melamed, A., Giordano, S. H., Ramirez, P. T., & Rauh-Hain, J. A. (2022). Employment disruption among women with gynecologic cancers. International Journal of Gynecological Cancer, 32(1), 69–78. https://doi.org/10.1136/ijgc-2021-002949

Shoushtari, A. N., Khan, S., Komatsubara, K., Feun, L., Acquavella, N., Singh-Kandah, S., Negri, T., Nesson, A., Abbate, K., Cremers, S., Musi, E., Ambrosini, G., Lee, S., Schwartz, G. K., & Carvajal, R. D. (2021). A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers, 13(21), 5504. https://doi.org/10.3390/cancers13215504

Balasubramanian, R., Min, X., Quinn, P. M. J., Giudice, Q. L., Tao, C., Polanco, K., Makrides, N., Peregrin, J., Bouaziz, M., Mao, Y., Wang, Q., da Costa, B. L., Buenaventura, D., Wang, F., Ma, L., Tsang, S. H., Fabre, P. J., & Zhang, X. (2021). Phase transition specified by a binary code patterns the vertebrate eye cup. Science Advances, 7(46). https://doi.org/10.1126/sciadv.abj9846

Sarkaria, S. M., Bao, S., Zhang, C., & Ding, L. (2021). Comprehensive Cellular Dissection of the Bone Marrow Microenvironment in Primary Myelofibrosis. Blood, 138(Supplement 1), 200–200. https://doi.org/10.1182/blood-2021-153727

Lipsky, A. H., Hill, B. T., Winter, A. M., Jurcic, J. G., Heaney, M. L., Rosenblat, T. L., Chiaramonte, M., Weissbrot, H., & Lamanna, N. (2021). High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 1555–1555. https://doi.org/10.1182/blood-2021-150914

Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D. A., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2021). Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 138(Supplement 1), 2318–2318. https://doi.org/10.1182/blood-2021-145344

Hill, B. T., Roth, C. J., Kositsky, R., Dave, T., Love, C., McKinney, M., Galal, A., Neff, J. L., Mian, A., Kendall, E., Ondrejka, S. L., Chiaramonte, M., Bhagat, G., Ofori, K., Reshef, R., Kovach, A. E., Sethi, T., Mason, E. F., Bhaskar, S., … Dave, S. S. (2021). Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 138(Supplement 1), 165–165. https://doi.org/10.1182/blood-2021-145764

Estrella, B., Liu, Y., Ricker, E. C., Pazos, M. A., Fiorito, J., Zuccarello, E., Calcagno, E., Honig, B., Arancio, O., & Amengual, J. E. (2021). Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas. Blood, 138(Supplement 1), 2254–2254. https://doi.org/10.1182/blood-2021-151442

Scuoppo, C., Cai, B., Ofori, K., Scholze, H., Basso, K., Pasqualucci, L., & Dalla-Favera, R. (2021). Repurposing NAD Salvage Inhibitors for GCB Diffuse Large-B Cell Lymphoma. Blood, 138(Supplement 1), 789–789. https://doi.org/10.1182/blood-2021-151079

Galan-Diez, M., Borot, F., Ali, A. M., Zhao, J., Gil-Iturbe, E., Shan, X., Huang, X.-P., Kurland, I., Roth, B. L., Quick, M., Mukherjee, S., Rabadan, R., Carroll, M. P., Raza, A., & Kousteni, S. (2021). A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia. Blood, 138(Supplement 1), 4456–4456. https://doi.org/10.1182/blood-2021-147741

Ricker, E. C., Ryu, Y. K., & Amengual, J. E. (2021). Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma. Blood, 138(Supplement 1), 4573–4573. https://doi.org/10.1182/blood-2021-150800

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2021). European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. Blood, 138(Supplement 1), 240–240. https://doi.org/10.1182/blood-2021-148020

Ricker, E. C., Estrella, B., Pazos, M. A., & Amengual, J. E. (2021). Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL. Blood, 138(Supplement 1), 2410–2410. https://doi.org/10.1182/blood-2021-153460

Hopson, M., Bhutani, D., Sarkaria, S. M., Maurer, M., Griffin, J., Lentzsch, S., & Chakraborty, R. (2021). Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 138(Supplement 1), 4726–4726. https://doi.org/10.1182/blood-2021-149299

Srisuwananukorn, A., Percha, B., Abu-Zeinah, G., Scandura, J., Krichevsky, S., Taylor, E., Silver, R. T., Thibaud, S., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., … Tremblay, D. (2021). Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. Blood, 138(Supplement 1), 2583–2583. https://doi.org/10.1182/blood-2021-150561

Lue, J. K., Ma, H., Marchi, E., Spivack, J. H., & O’Connor, O. A. (2021). Peripheral T-Cell Lymphoma Involvement of the Central Nervous System: Impact of Novel Therapeutics on Clinical Outcomes. Blood, 138(Supplement 1), 2469–2469. https://doi.org/10.1182/blood-2021-144933

De Botton, S., Yee, K., Recher, C., Wei, A. H., Montesinos, P., Taussig, D., Pigneux, A., Braun, T., Curti, A., Esteve, J., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan Sangerman, M., Blum, W. G., Cilloni, D., Hiwase, D., … Fenaux, P. (2021). Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 138(Supplement 1), 2351–2351. https://doi.org/10.1182/blood-2021-144912

Garcia, J. S., Wei, A. H., Jacoby, M. A., Fong, C. Y., Borate, U., Baer, M. R., Cunningham, I., Odenike, O., Jurcic, J. G., Nowak, D., Peterlin, P., Platzbecker, U., Dunshee, D., Zhou, Y., Hoffman, D., Sun, Y., Popovic, R., Ainsworth, B., Naqvi, K., … Garcia-Manero, G. (2021). Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood, 138(Supplement 1), 241–241. https://doi.org/10.1182/blood-2021-145613

Lee, H. J., Choi, M., Siddiqi, T., Barrientos, J., Wierda, W. G., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L. A., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, Y., Wang, M., Jamieson, C., & Kipps, T. J. (2021). Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 3534–3534. https://doi.org/10.1182/blood-2021-148779

Crowley, L., & Shen, M. M. (2022). Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies. Cancer Letters, 525, 108–114. https://doi.org/10.1016/j.canlet.2021.10.035

Symeonides, S., Evans, J., Arkenau, H.-T., McKean, M., Lakhani, N., Lim, E., Falchook, G., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., & Bexon, A. (2021). CTNI-49. PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 23(Supplement_6), vi71–vi71. https://doi.org/10.1093/neuonc/noab196.274